Approved for use through 04/30/2003. OMB 0651-0031

Barre	Substitute for Form 1449/PTO	Complete if Known		
1.20		Application Number	10/531,540	
	INFORMATION DISCLOSURE	Filing Date	April 15, 2005	
	STATEMENT BY APPLICANT	First Named Inventor	Stanka PERC	
	(Use as many sheets as necessary)	Art Unit		
	(Ose as many shoots as necessary)	Examiner Name		
	Sheet 1 of 2	Attorney Docket Number	4061-27PUS	

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind-Code ^{2 (if} known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-6,906,062	06/14/2005	Chhabada et al.	
		US-			
		US-			1
		US-			
•		US-			
		US-			
-		US-			
		US-			

Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	L _e
	Country Code ³ Number ⁴ Kind-Code ⁵ (if known)			Relevant Figures Appear	
	WO 03/026610	04/03/2003	Ranbaxy Laboratories		
	EP 0830864 A1	03/25/1998	Eli Lilly & Co.		
	DE 69718731 T2	09/11/2003	Eli Lilly & Co.		000000000000000
	WO 99/61027	12/02/1999	Eli Lilly & Co.		
		No. 1 Country Code 1 Number 1 Kind-Code 5 (if known WO 03/026610 EP 0830864 A1 DE 69718731 T2	No. 1 Country Code 1 Number 1 Kind-Code 5 (if brown Kind-Code 5 (i	No. Country Code Number MM-DD-YYYY Applicant of Cited Document WO 03/026610 04/03/2003 Ranbaxy Laboratories EP 0830864 A1 03/25/1998 Eli Lilly & Co. DE 69718731 T2 09/11/2003 Eli Lilly & Co.	No. Country Code ³ Number MM-DD-YYYY Applicant of Cited Document Where Relevant Passages or Relevant Figures Appear WO 03/026610 04/03/2003 Ranbaxy Laboratories EP 0830864 A1 03/25/1998 Eli Lilly & Co. DE 69718731 T2 09/11/2003 Eli Lilly & Co.

Examiner Signature	/Samira Jean-louis/	Date Considered	12/31/2008	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO					Complete if Known		
					Application Number	10/531,540	
INEOI) M A TIO	NI TATO	CT OS	пот	Filing Date	April 15, 2005	
INFORMATION DISCLOSURE					First Named Inventor	Stanka PERC	
STATEMENT BY APPLICANT (Use as many sheets as necessary)			ANT	Art Unit			
	(Use as many s	neets as ne	ecessary)		Examiner Name		
Sheet	2	of	2		Attorney Docket Number	4061-27PUS	

Examiner Initials*	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T ²
Examiner initials*	No. 1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		Belda et al., The Tabletting Behaviour of Cellactose® Compared with	
		Mixtures of Celluloses with Lactoses, Eur. J. Pharm. Biopharm. 42(5) 325-330 (1996).	
		Remington: The Science of Practice of Pharmacy, 19 th Edition (1995).	
***************************************		Encyclopedia of Pharmaceutical Technology: Volume 4, Direct	
		Compression Tableting, British Library	
	-		
			+
			+
			_
			Щ.

Examiner Signature	/Samira Jean-Iouis/	Date Considered	12/31/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.